of eosinophils. A culture of at least one lesion will rule out staphylococcus infection, which has been significantly linked to atopic dermatitis. Treatment Prurigo nodularis is very hard to treat, but current therapies include steroids, Dupixent, vitamins, cryosurgery, thalidomide and UVB light. In the event that staphylococcus or other infection is present, antibiotics have proven effective, but tend to cause more harm than good for this particular disease. A physician may administer a strong dose of prednisone, which will almost immediately stop the itch/scratch cycle. However, cessation of steroids allows relapse to occur, usually within a few weeks. Horiuchi et al recently reported significant improvement in PN with antibiotic therapy. Another drug a physician may administer is Apo-Azathioprine. Azathioprine, also known by its brand name Imuran, is an immunosuppressive drug used in organ transplantation and autoimmune diseases and belongs to the chemical class of purine analogues. Dupixent was the first medication approved by the FDA in September 2022 to treat Prurigo Nodularis. History Prurigo nodularis was first described by Hyde and Montgomery in 1909. See also Pruritus Skin lesion Notes External links DermNet NZ: Prurigo nodularis Pruritic skin conditions Ailments of unknown cause